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) and molecules with similar over-
lapping functions are important for immune responses to
pathogens. Many lines of evidence suggest that they are also
critical for the initiation and maintenance of pathogenic au-
toimmune responses such as that which causes insulin-depen-





 and related molecules such as interleukin-12 (IL-12) are




 induces several of the
pathologies associated with IDDM including immune activa-
tion, inflammation, autoreactivity, and tissue destruction (1).
In the spontaneous animal model of diabetes, the nonobese di-




expression correlates with disease onset. Additionally, neutral-




 block disease transfer. Another cy-
tokine molecule with overlapping functions, IL-12, is also ex-
pressed prior to the onset of disease in the NOD mouse.
Recent work has demonstrated that treatment of NOD mice
with IL-12 accelerates and exacerbates disease development.
It is not known how or why, in genetically predisposed individ-
uals, these cytokine molecules are elicited. Recent interesting





implicated the disregulation of a comparatively new molecule
in the cytokine arena, interferon-gamma inducing factor
(IGIF), as mediating the overproduction of these potentially
destructive inflammatory mediators in disease susceptible indi-
viduals (2).
This newly discovered molecule IGIF (now designated in-
terleukin-18) was originally isolated from the liver where it has




 inducing activity (3). IGIF




 inducing capabilities than the
cytokine IL-12 and apparently utilizes a distinct signal trans-
duction pathway for its elicitation. Studies thus far imply that
IGIF has a T helper 1 type pattern of induction of cytokine




 production, but decreases
IL-10 production. Interestingly no effect on IL-4 expression
was observed (4). The induction of Th1 type cytokines is gen-
erally thought to be necessary for cell mediated autoimmune
diseases such as IDDM. Indeed the presence of IGIF has been
demonstrated to be critical for damage to occur in a murine
model for bacteria induced liver damage. In the current issue
of JCI, the first report correlating this molecule with autoim-
mune diabetes is indeed provocative. In this study, the expres-
sion pattern of IGIF was determined in IDDM susceptible
NOD mice as well as diabetes resistant strains. Additionally,
genetic linkage analysis was performed. The results point to a
critical importance for IGIF in spontaneous diabetes in the
NOD mouse. In this study the authors report that levels of
IGIF rise very rapidly after cyclophosphamide treatment and




. Strikingly, the cyclophosphamide
inducibility of IGIF was not seen in the non-diabetes prone
strain studied by these authors. This indicates a fundamental




 inducing function in
macrophages of NOD mice and the diabetes resistant strain.
Interestingly, the authors demonstrated that IGIF gene maps
to an interval of chromosome 9 where a diabetes susceptibility
gene from the NOD mouse (Idd2) has been located. 
The action and identity of diabetes susceptibility genes rep-
resents an important area for consideration of disease mecha-
nism in both animals and humans. Of course, the rodent popu-
lations are more accessible experimentally. In intercrosses
between the disease susceptible NOD mouse and the disease
resistant C57BL/10 strain, it has been revealed that genetic dif-
ferences exist that contribute to the likelihood that any indi-
vidual will develop disease. Years of analysis of genetic crosses
between the NOD mouse and the C57BL/10 mouse have re-
vealed at least ten of these traits and their location of the chro-
mosome has been mapped and termed Idd loci (5). With the
exception of the MHC, which is universally required, the other
genes appear to have an additive effect on the likelihood of
any individual mouse succumbing to the disease. Importantly,
when different inbred strains were analyzed in this manner dis-
tinct sets of genetic differences were revealed, each contribut-
ing to disease susceptibility and resistance. This complexity il-
lustrates an important truth regarding genetic susceptibility to
diabetes: that predisposition is a very exquisite interaction of
comparative “defects” conferred by susceptibility loci and
“ability to overcome them” in resistance loci. Within any indi-
vidual intercross mouse (and in humans) these will vary, at
least to some extent. The Idd2 locus is one of these susceptibil-
ity locations on the NOD chromosome. It has been revealed in
backcrosses with the C57Bl/10 mouse and also more recently
in crosses with a second strain, NON, increasing its signifi-
cance. While the exact length of the interval is unknown, the
Idd2 locus could be presumed to encompass the coding regions
for many genes. Thus, it will certainly be important to deter-
mine whether a difference exists in the NOD IGIF allele com-
pared with the non-disease susceptible BALB/c mouse, stud-
ied in the current report. In this case there may be a difference
in the regulatory region of the gene since its expression was
upregulated in NOD mice following cyclophosphamide treat-
ment but was not upregulated in BALB/c mice, implying a reg-
ulatory, not a structural, polymorphism.
The pathway toward disease in genetically predisposed in-
dividuals with different combinations of susceptibility genes is
predicted to be at least subtly distinct. The reported dysregula-
tion of the IGIF molecule in NOD mice may be one way to
cause a pathogenic Th1 response that could lead to autoimmu-
nity. However, there is probably more than one molecular
pathway to disease, even within the overwhelmingly geneti-





pression leads to inflammatory autoimmune disease and treat-




eliminates disease, it was recently demonstrated that the ge-




 gene from NOD mice does not





prevent the diabetes from ultimately occurring (6). This para-
dox illustrates the redundancy within the NOD autoaggressive
system, and in general for the cytokines involved in regulating
cell mediated immunity. For determination of disease-causing
potential it is far more significant that an elicited molecule can
mediate disease, than the antithetical situation where the me-
diator has never been there at all. In the current study both
IL-12 and IL-18 show overlapping function in their ability to




; and all three molecules share spe-
cific immune stimulatory properties in common. The NOD
mouse maximizes these pathogenic redundancies, since not all
Idd loci mapped are required for disease. We can still look for
a central mechanism within these distinct pathways, since mol-
ecules of similar function form a cascade with a finite number
of possibilities.
The net result of the genetic interactions is elicitation of
molecules like IGIF and pathogenic immune stimulation. Mac-
rophage activation and release of interferon-gamma leads to
expression of costimulatory molecules and priming of islet an-
tigen specific T cells (1). This T cell activation fuels the specific
loss of pancreatic beta cells. Important work such as that de-
scribed in the current issue of JCI on IGIF furthers the identi-
fication of molecules that provide the molecular basis for initi-
ation of disease and allow for the development of therapeutic
strategies of increased range and efficacy.
Nora Sarvetnick
Departments of Immunology and Neuropharmacology
The Scripps Research Institute
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